Landscape Capital Management L.L.C. raised its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 126.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 167,157 shares of the company's stock after buying an additional 93,374 shares during the quarter. Landscape Capital Management L.L.C. owned 0.19% of Progyny worth $2,802,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Intech Investment Management LLC lifted its position in shares of Progyny by 282.0% during the 3rd quarter. Intech Investment Management LLC now owns 42,013 shares of the company's stock valued at $704,000 after acquiring an additional 31,014 shares during the period. Aurora Investment Counsel bought a new stake in Progyny in the third quarter valued at $1,280,000. King Luther Capital Management Corp raised its holdings in shares of Progyny by 39.1% during the third quarter. King Luther Capital Management Corp now owns 164,760 shares of the company's stock valued at $2,761,000 after purchasing an additional 46,281 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Progyny during the 3rd quarter worth about $77,000. Finally, Sugar Maple Asset Management LLC acquired a new stake in shares of Progyny in the 3rd quarter valued at about $176,000. 94.93% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the company. Jefferies Financial Group decreased their price objective on Progyny from $31.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, September 19th. Truist Financial restated a "hold" rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Canaccord Genuity Group lowered shares of Progyny from a "buy" rating to a "hold" rating and dropped their price objective for the company from $37.00 to $24.00 in a research note on Wednesday, August 7th. Barclays decreased their target price on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. cut their price target on Progyny from $31.00 to $22.00 and set an "overweight" rating for the company in a research note on Thursday, September 19th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Progyny presently has a consensus rating of "Hold" and an average price target of $25.42.
Check Out Our Latest Research Report on PGNY
Progyny Stock Up 2.3 %
Shares of NASDAQ PGNY opened at $13.98 on Thursday. The company has a market capitalization of $1.19 billion, a PE ratio of 24.10, a PEG ratio of 1.65 and a beta of 1.44. The stock's 50 day moving average price is $16.74 and its 200-day moving average price is $22.92. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $42.08.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter last year, the business posted $0.16 earnings per share. The business's revenue was up 2.0% compared to the same quarter last year. As a group, research analysts expect that Progyny, Inc. will post 0.56 EPS for the current fiscal year.
Progyny Company Profile
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Recommended Stories
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
